Iterable Launches Native WhatsApp Integration to Power Real-Time, Two-Way Messaging at Global Scale
Select Iterable customers are already using WhatsApp to deliver personalized offers, send timely updates, and respond instantly to customer behavior—all seamlessly orchestrated alongside other channels in Iterable. It's a smarter, faster way to meet customers where they are—and turn everyday interactions into moments that build trust, deepen loyalty, and accelerate growth.
"This isn't just another channel—it's a strategic unlock for marketers," said Andrew Boni, CEO and founder of Iterable. "By bringing WhatsApp into our AI-powered platform, we're giving marketers the ability to reach global audiences with precision, speed, and personalization. With Iterable, every WhatsApp message becomes part of a cohesive, intelligent journey, where customer context drives action and connection at scale."
What Sets Iterable's WhatsApp Integration Apart
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
30 minutes ago
- Business Wire
PROS Holdings, Inc. Announces Date of Second Quarter 2025 Financial Results Release, Conference Call, and Webcast
HOUSTON--(BUSINESS WIRE)-- PROS ® (NYSE: PRO), a leading provider of AI-powered SaaS pricing and selling solutions, will release its financial results for the second quarter 2025 ended June 30, 2025, after the U.S. financial markets close on Thursday, July 31, 2025. PROS Holdings, Inc. will host a conference call on Thursday, July 31, 2025, at 4:45 p.m. ET to discuss the company's financial results and business outlook. To access this call, dial 1-877-407-9039 (toll-free) or 1-201-689-8470. The live and archived webcasts of this call can be accessed under the 'Investor Relations' section of the Company's website at A telephone replay will be available until Thursday, August 7, 2025, at 11:59 PM ET at 1-844-512-2921 (toll-free) or 1-412-317-6671 using the pass code 13754225. About PROS PROS Holdings, Inc. (NYSE: PRO) helps the world's leading companies outperform across the top and bottom line. Leveraging leadership in revenue and pricing science, the PROS Platform combines predictive AI, real-time analytics and powerful automation to dynamically match offer to buyer and price to product, accelerating revenue growth and maximizing profit. With solutions spanning pricing, revenue management, offer marketing and CPQ, PROS helps businesses optimize transactions across every channel. Learn more at
Business Wire
35 minutes ago
- Business Wire
Aqtual Raises Over $30M as It Scales Novel cfDNA Platform
HAYWARD, Calif.--(BUSINESS WIRE)-- Aqtual, Inc., a precision medicine company using its novel active chromatin cell-free DNA (cfDNA) platform to develop products for chronic diseases and oncology, today announced it has raised $31 million in Series B funding. Three new investors, including Bold Capital and Bold Longevity Growth Fund, joined previous investors Genoa Ventures, Manta Ray Ventures, and Yu Galaxy in participating in the oversubscribed round. Additional capital was also provided by a strategic investor in the diagnostics space, further strengthening Aqtual's ability to advance the platform and its applications as it moves towards the commercialization of Aqtual's first flagship product: a therapy response prediction test in rheumatoid arthritis (RA). Aqtual is actively enrolling RA patients in a prospective observational clinical trial, PRIMA-102 (ID NCT05936970). The trial, with more than 1,300 patients enrolled, has delivered initial proof-of-concept data and is expected to be completed in Q4 2025. RA treatment remains highly individualized, with many patients cycling through multiple therapies before achieving disease control. In the U.S. alone, RA contributes over $19 billion annually in direct healthcare costs, excluding the broader burden of reduced quality of life, disability, and premature mortality. 'The Aqtual team combines deep technical brilliance with remarkable resilience and ingenuity,' said Lawrence Barclay, Managing Partner at Manta Ray. 'Over the past year, we've seen powerful signals of technical and early commercial validation – not only in their lead indication, but across a broad range of chronic diseases and cancers – demonstrating the platform's potential for wide-reaching impact in molecular diagnostics. It's been a pleasure to work with them over the years, and Manta Ray is excited to support this next pivotal step toward commercialization.' Aqtual's proprietary active chromatin cfDNA platform is the first to integrate DNA, epigenetic regulation, and protein-DNA binding in a single, blood-based assay. Its proprietary approach enables high-fidelity quantification of tissue-specific gene regulation directly from blood through integrated profiling of disease, microenvironment, and systemic immune response. 'This raise marks a key inflection point for cfDNA diagnostics—not just for Aqtual, but for the broader field,' said Diana Abdueva, Ph.D., co-founder and CEO of Aqtual. 'Our platform uniquely captures the biology of chronic disease, enabling deeper insights to support more effective treatment planning strategies. With this funding, strengthened by backing from a strategic partner, we're positioned to advance our internal pipeline and forge new partnerships that extend the impact of our platform across disease areas.' Aqtual will present new data and commercialization plans at major rheumatology and diagnostics meetings in the second half of 2025, including the Congress of Clinical Rheumatology (CCR) West, the Coalition of State Rheumatology Organizations (CSRO) Advocacy Conference, and American College of Rheumatology (ACR) Convergence 2025. For more information, please visit About Aqtual, Inc. Aqtual, Inc. is a precision medicine company developing products for chronic disease management and oncology utilizing a novel cell-free DNA-based platform. Aqtual's proprietary platform evaluates protein regulation, epigenetics, and transcriptomics solely using cell-free DNA fragments found in the blood. The platform yields efficient and robust real-time analysis of disease and treatment while overcoming the limitations of previous cell-free DNA methodologies.
Business Wire
35 minutes ago
- Business Wire
CNC INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Centene Corporation Investors with Substantial Losses Have Opportunity to Lead the Centene Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that the Centene Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.), the Centene class action lawsuit charges Centene and certain of Centene's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Centene class action lawsuit, please provide your information here: CASE ALLEGATIONS: Centene is a healthcare enterprise that provides fully integrated services to government-sponsored and commercial healthcare programs, focusing on underinsured and uninsured individuals. The Centene class action lawsuit alleges that defendants throughout the Class Period created the false impression that they possessed reliable information pertaining to Centene's projected revenue outlook and anticipated growth while also touting enrollment rates and low morbidity. In truth, Centene's optimistic reports and promises regarding Centene's inflated guidance fell short of reality when a preliminary analysis of over two-thirds of Centene's marketplace share showed lower-than-anticipated enrollment and increased aggregate market morbidity, according to the complaint. The Centene class action lawsuit further alleges that, on July 1, 2025, Centene withdrew its 2025 guidance. Particularly, following an analysis of the 2025 Health Insurance Marketplace, Centene's overall market growth across 22 states, or 72% of Centene's marketplace membership, was lower than expected, according to the complaint. Centene also stated that this preliminary analysis resulted in a reduction of its previously issued guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75, the Centene class action lawsuit alleges. On this news, the price of Centene stock fell by more than 40%. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Centene securities during the Class Period to seek appointment as lead plaintiff in the Centene class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Centene class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Centene class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Centene class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
